Contribute Try STAT+ Today

Hours after the biotech company Iovance announced yet another regulatory delay for its investigational cancer treatment, the firm disclosed Wednesday that its CEO had abruptly tendered her resignation, sending its share price plummeting.

Maria Fardis, who has run Iovance since 2016, informed the company on Tuesday that she “will be resigning” from her roles as CEO, president, and board member, the firm said in a two-sentence filing with the Securities and Exchange Commission. Iovance did not specify whether Fardis’s resignation was effective immediately, and the company did not immediately respond to an inquiry. She’s leaving to “pursue other opportunities,” the company said in its filing, and she’ll be replaced on an interim basis by Iovance general counsel Frederick Vogt.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.